InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,416.76
(
-1.91%
)
US TECH 100
18,281.20
(
-2.98%
)
Dow Jones
40,150.61
(
-1.69%
)
Brent Oil
79.76
(
-2.15%
)
Bitcoin
62,860.18
(
-2.69%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120182
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: croumagnon post# 7556

Monday, 02/04/2008 6:41:04 PM

Monday, February 04, 2008 6:41:04 PM

Post# of 19309
I misread goseek’s question and thought he was asking about the rate of DVT in untreated patients with HD who undergo at-risk procedures.

To be clear: there should be no difference between ATryn and plasma-derived AT in efficacy at preventing DVT. This is ’s the reason the phase-3 trial was designed as a non-inferiority study.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up